ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Sofosbuvir-Based Regimen in Treatment Experienced-Post Liver Transplant Patients with Hepatitis C Recurrence.

A. Ajlan,1 A. Aljedai,1 H. Elsiesy,2 D. Alkortas,1 R. Alarieh,2 W. Alhumodi,2 D. Broring,2 M. Alsebayel,2 F. Aba Alkhail.2

1Pharmaceutical Care, KFSHRC, Riyadh, Saudi Arabia
2Liver and Small Bowel Transplant, KFSHRC, Riaydh, Saudi Arabia.

Meeting: 2016 American Transplant Congress

Abstract number: D295

Keywords: Hepatitis C, Liver transplantation

Session Information

Date: Tuesday, June 14, 2016

Session Name: Poster Session D: Viral Hepatitis

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Related Abstracts
  • Sofosbuvir-Based Therapy for Hepatitis C Recurrence Post Liver Transplantation
  • Efficacy of Sofosbuvir Based Therapy for Recurrent Hepatitis C After Liver Transplantation

This is an open label, prospective, interventional cohort study conducted at a tertiary referral center. The primary end point is SVR12 in patients treated with sofosbuvir therapy for post liver transplant HCV recurrence. A total of 50 treatment experienced post liver transplant patients with histologic HCV recurrence received sofosbuvir and ribavirin ± peginterferon. Of those 50 patients, 34 (68%) were GT 4, 3 (6%) GT 2, 3 (6%) mixed GT 1&4 and 9 (18%) GT 1, and one patient had GT 3 (2%). All patients completed the follow up period. Mean Age was 60 years, the cohort included 32 males, and three patients had cirrhosis. Mean baseline HCV RNA was 8.3 log10 IU/ml. The majority of patients had ≥ stage 2 fibrosis on liver biopsy. Thirty-one patients were treated with pegylated interferon plus ribavirin in addition to sofosbuvir for 12 weeks and the remaining were treated with sofosbuvir plus ribavirin only for 24 weeks. By week 4, seven patients had detectable HCV RNA. Of the 50 patients, 46 (92%) achieved SVR12 and 4 patients (8%) relapsed. Our results suggest that sofosbuvir based regimen can be utilized successfully to treat liver transplant patients with HCV recurrence. (Clinical trial number # RAC 2141038).

CITATION INFORMATION: Ajlan A, Aljedai A, Elsiesy H, Alkortas D, Alarieh R, Alhumodi W, Broring D, Alsebayel M, Aba Alkhail F. Sofosbuvir-Based Regimen in Treatment Experienced-Post Liver Transplant Patients with Hepatitis C Recurrence. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Ajlan A, Aljedai A, Elsiesy H, Alkortas D, Alarieh R, Alhumodi W, Broring D, Alsebayel M, Alkhail FAba. Sofosbuvir-Based Regimen in Treatment Experienced-Post Liver Transplant Patients with Hepatitis C Recurrence. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/sofosbuvir-based-regimen-in-treatment-experienced-post-liver-transplant-patients-with-hepatitis-c-recurrence/. Accessed March 4, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.